RESEARCHER PROFILE

Charles A. Gersbach

← Back to The Wallace H. Coulter Department of Biomedical Engineering

C

The Wallace H. Coulter Department of Biomedical Engineering

CRISPR and Genetic EngineeringVirus-based gene therapy researchGenomics and Chromatin DynamicsRNA Interference and Gene DeliveryPluripotent Stem Cells Research

Charles A. Gersbach works in CRISPR and Genetic Engineering, Virus-based gene therapy research, Genomics and Chromatin Dynamics, RNA Interference and Gene Delivery, Pluripotent Stem Cells Research. Recorded institutional associations include Emory University, Duke University, The Wallace H. Coulter Department of Biomedical Engineering.

258Publications
23,570Citations
68H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

    2013 · 3,811 citations
  2. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers

    2015 · 1,885 citations
  3. The next generation of CRISPR–Cas technologies and applications

    2019 · 1,455 citations
  4. RNA-guided gene activation by CRISPR-Cas9–based transcription factors

    2013 · 1,323 citations
  5. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

    2015 · 1,141 citations
  6. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements

    2015 · 1,006 citations
  7. Genome-editing Technologies for Gene and Cell Therapy

    2016 · 719 citations
  8. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation

    2015 · 637 citations
  9. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy

    2015 · 468 citations
  10. Editing the epigenome: technologies for programmable transcription and epigenetic modulation

    2016 · 449 citations
  11. CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome

    2017 · 444 citations
  12. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy

    2019 · 430 citations
  13. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

    2014 · 383 citations
  14. Increasing the specificity of CRISPR systems with engineered RNA secondary structures

    2019 · 351 citations
  15. The once and future gene therapy

    2020 · 321 citations
  16. How vinculin regulates force transmission

    2013 · 260 citations
  17. Synergistic and tunable human gene activation by combinations of synthetic transcription factors

    2013 · 242 citations
  18. Loss-of-function genetic tools for animal models: cross-species and cross-platform differences

    2016 · 220 citations
  19. Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells

    2016 · 219 citations
  20. Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries

    2004 · 203 citations
  21. A CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification

    2014 · 196 citations
  22. Light-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors

    2012 · 192 citations
  23. Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients

    2013 · 181 citations
  24. RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors

    2018 · 178 citations
  25. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models

    2021 · 175 citations

← Return to the university profile